Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

Summary

The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.

Timeline

Start

2015-09-01

Primary completion

2017-07-21

Completion

2017-07-21

Drugs

Indications